A Phase 2 interventional study of Sotatercept 0.3 mg/kg and Placebo in Hypertension, Pulmonary, sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA. Completed at 119 sites in 12 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 397 studies in Hypertension, Pulmonary with a site in United States — 73 open to participants now, 87 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.
Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 60th largest by enrollment of the 286 interventional ones that give a count, is one of 12 that started in 2021, is one of 93 in phase 2, and was the 311th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →73 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–80
University of California, Davis · Sites in United States
Ages up to 28 days
Tectonic Operating Company, Inc. · Sites in United States, Poland, Romania and 3 more countries
Ages 18–80
35Pharma Inc., a GSK company · Sites in United States
Ages 18+
National Institutes of Health Clinical Center (CC) · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
397 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 114 · Phase 3 75 · Phase 4 38
First in 1992; this study’s year is marked. 12 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 165 is above the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 30 across the 286 interventional studies, 108 across the 107 observational. Of the 273 that completed or were terminated, 139 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
158 of 397 have an industry lead sponsor. The 10 most frequent:
This study is registered under Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, one of the names counted as Merck & Co., Inc. Under that name alone:
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA is the lead sponsor of 26 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Merck & Co., Inc has 9 studies filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
21 of the studies in Hypertension, Pulmonary with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06616974Tectonic TherapeuticA Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | 2026-11-24 |
| NCT07333183Pulmovant, Inc.A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | 2026-12 |
| NCT05442671Children's Hospital of PhiladelphiaiTONE Trial (exercIse Training in pulmONary hypertEnsion) Exercise Program for Pediatric PH | 2026-12-31 |
| NCT04808596University of Kansas Medical CenterPulmonary Hypertension Biorepository and Registry | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 397 studies in Hypertension, Pulmonary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
The objective of this study is to evaluate the efficacy, safety and tolerability of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk distance (6MWD, key secondary endpoint).
Participants enrolled in the study will have a diagnosis of Cpc-PH due to HFpEF with New York Heart Association (NYHA) functional class (FC) II or III. Participants will be randomly assigned in a 1:1:1 ratio to 1 of the 3 treatment groups (placebo, 0.3mg/kg sotatercept and 0.7mg/kg sotatercept) during the placebo-controlled Treatment Period. In the extension phase, sotatercept-treated participants will continue on their current dose. Placebo participants will be re-randomized in a 1:1 ratio to one of the two sotatercept treatment groups utilized in the placebo-controlled Treatment Period. Each participant will be enrolled in the study for up to 114 weeks, including a 28-day Screening Period, a 24-week, double-blind, placebo-controlled Treatment Period, an 18-month Extension Period, and an 8-week Follow-up Period.
As of protocol amendment 6, the 18-month Extension Period is being removed. Participants who have completed at least the 24-week placebo controlled treatment period and the end of study visit, and who have not discontinued study treatment early, may be eligible to participate in an extension study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet the following criteria to be enrolled in this proof-of-concept study:
Clinical diagnosis of HFpEF:
Demonstrated Cpc-PH by all of the following:
Women of must:
Male participants must:
Exclusion Criteria:
Participants will be excluded from the study if any of the following criteria are met:
and active lung disease:
Cardiovascular co-morbidities, which include any of the following:
Any of the following clinical laboratory values prior to Visit 1 as specified:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Delivered subcutaneously (SC) every 3 weeks (Q3W) for 24 weeks in the placebo-controlled treatment period.
Drug: Placebo
Participants will receive sotatercept SC at a dose level of 0.3 mg/kg Q3W for 24 weeks in the placebo-controlled treatment period.
Drug: Sotatercept 0.3 mg/kg
Sotatercept SC at a starting dose level of 0.3 mg/kg for 3 dosing visits (Q3W), then escalating to 0.7 mg/kg SC on the fourth dosing visit and Q3W for the remainder of the 24-week treatment Period.
Drug: Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
Drug page: Sotatercept
Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
Also known as: ACE-011
Administered by subcutaneous injection
Drug page: Sotatercept
Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
Also known as: ACE-011
Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24
PVR, a hemodynamic variable of pulmonary circulation, was measured by right heart catheterization (RHC). Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Time frame: Baseline and Week 24
Base Study: Change From Baseline in the 6-Minute Walk Distance (6MWD) at Week 24
The 6MWD was performed to assess functional capacity. The 6MWD was assessed using the 6-minute walk test (6MWT) to measure the distance covered over a time period of 6 minutes. An increase in the distance walked during the 6MWT indicated improvement in functional exercise capacity. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Time frame: Baseline and Week 24
Base Study: Time to First Clinical Worsening Event (TTCW) at Weeks 24
Clinical Worsening events were defined as the number of weeks from first dose date to any of the following: * Hospitalization due to a cardiopulmonary indication (a non-elective hospitalization lasting at least 24 hours in duration caused by clinical conditions directly related to Pulmonary Hypertension and/or Heart Failure) * Administration of intravenous diuretics or subcutaneous (SC) furosemide * Death (all causes) * Decrease in 6 minute walk distance (6MWD) by ≥15% from baseline confirmed by 2 tests at least 4hours, but no more than 1 week apart.
Time frame: 24 Weeks
Base Study: Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) at Week 24
mPAP was calculated from systolic and diastolic pulmonary artery pressure measured by right heart catheterization. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Time frame: Baseline and Week 24
Base Study: Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 24
PCWP is an indirect estimate of left atrial pressure measured in right heart catheterization. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Time frame: Baseline and Week 24
Base Study: Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at Week 24
TAPSE is an echocardiographic measurement of tricuspid valve annulus movement, as an indicator of right heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Time frame: Baseline and Week 24
Base Study: Change From Baseline in Right Ventricular Fractional Area Change (RVFAC) at Week 24
RVFAC is an echocardiographic measurement of percent change between right ventricular area during diastole and systole, as an indicator of right heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Time frame: Baseline and Week 24
Base Study: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Week 24
LVEF is an echocardiographic measurement of percent change between left ventricular volume during diastole and systole, as an indicator of left heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Time frame: Baseline and Week 24
Base Study: Change From Baseline in Isovolumic Relaxation Time (IVRT) at Week 24
IVRT is an echocardiographic measurement of the interval between closure of the aortic valve, to onset of filling by opening of the mitral valve. It was used as an indicator of diastolic dysfunction. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Time frame: Baseline and Week 24
Base Study: Change From Baseline in Ratio of Mitral Inflow Velocity E to Mitral Annular Velocity'(e') (E/e' Ratio) at Week 24
E/e' is a ratio of mitral inflow velocity E to mitral annular velocity (e') as measured by electrocardiography as an indicator of diastolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Time frame: Baseline and Week 24
Base Study: Change From Baseline in the Ratio of the Peak Velocity Flow of the E Wave in Early Diastole to Peak Velocity Flow of the A Wave in Late Diastole (E/A Ratio) at Week 24
E/A is a ratio of the peak velocity flow of the E wave in the early diastole to peak velocity flow of the A wave in late diastole measured by echocardiography as an indicator of diastolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Time frame: Baseline and Week 24
Base Study: Change From Baseline in N-terminal Pro-hormone Brain Natriuretic Peptide (NT-proBNP) at Week 24
NT-proBNP is a circulating biomarker that reflects myocardial stretch. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Time frame: Baseline and Week 24
Base Study: Change From Baseline in New York Heart Association Functional Class (NYHA FC) at Week 24
NYHA FC classified the extent of heart failure (HF). Participant HF symptoms were graded using the NYHA FC system. NYHA FC for HF ranges from Class I (no limitation of physical activity, or ordinary physical activity does not cause undue fatigue, palpitation, dyspnea \[shortness of breath\]), Class II (slight limitation of physical activity, comfortable at rest, or ordinary physical activity results in fatigue, palpitation, dyspnea \[shortness of breath\]), Class III (marked limitation of physical activity, comfortable at rest, or less than ordinary activity causes fatigue, palpitation, or dyspnea) and Class IV (unable to carry on any physical activity without discomfort, symptoms of HF at rest or if any physical activity is undertaken, discomfort increases). Participants were classified as "Improved or Maintained" or "Not Improved nor Not Maintained". Improved or Maintained = reduction in NYHA FC or no change in NYHA FC; Not Improved nor Not Maintained = increase in NYHA FC.
Time frame: Baseline and Week 24
Base Study: Change From Baseline in Myocardial Contraction Fraction (MCF) at Week 24
MCF is an echocardiographic measurement that determined the ratio of left ventricular stroke volume to myocardial volume and was an indicator of left ventricular systolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Time frame: Baseline and Week 24
Base Study: Number of Participants With One or More Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE was reported.
Time frame: Up to approximately 6 months
Base Study: Number of Participants Who Discontinued Study Treatment Due to an AE
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE was reported.
Time frame: Up to approximately 6 months
| Milestone | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo | Extension Period: Sotatercept 0.3 mg/kg | Extension Period: Sotatercept 0.7 mg/kg | Extension Period: Placebo → Sotatercept 0.3 mg/kg | Extension Period: Placebo → Sotatercept 0.7 mg/kg |
|---|---|---|---|---|---|---|---|
| Started | 54 | 56 | 55 | 0 | 0 | 0 | 0 |
| Completed | 52 | 49 | 49 | 0 | 0 | 0 | 0 |
| Not completed | 2 | 7 | 6 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 3 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized in error without receiving study treatment | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Change in health status | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Unwillingness or inability to comply with protocol | 1 | 2 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo | Extension Period: Sotatercept 0.3 mg/kg | Extension Period: Sotatercept 0.7 mg/kg | Extension Period: Placebo → Sotatercept 0.3 mg/kg | Extension Period: Placebo → Sotatercept 0.7 mg/kg |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 52 | 47 | 22 | 23 |
| Completed | 0 | 0 | 0 | 27 | 20 | 12 | 10 |
| Not completed | 0 | 0 | 0 | 25 | 27 | 10 | 13 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 3 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 3 | 7 | 0 | 2 |
| Withdrew: Participants ongoing | 0 | 0 | 0 | 16 | 16 | 7 | 9 |
| Withdrew: Elevation of hemoglobin values | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Worsening hemodynamics | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Participant request, did not withdraw consent | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Unwillingness or inability to comply with protocol | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
PVR, a hemodynamic variable of pulmonary circulation, was measured by right heart catheterization (RHC). Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
| dynes*sec/cm5 | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo |
|---|---|---|---|
| Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24 | -53.7 (-67.2 to -47.7) | -26.0 (-36.4 to -3.5) | 21.1 (16.7 to 24.8) |
The 6MWD was performed to assess functional capacity. The 6MWD was assessed using the 6-minute walk test (6MWT) to measure the distance covered over a time period of 6 minutes. An increase in the distance walked during the 6MWT indicated improvement in functional exercise capacity. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
| Meters | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo |
|---|---|---|---|
| Base Study: Change From Baseline in the 6-Minute Walk Distance (6MWD) at Week 24 | 14.2 (10.1 to 16.3) | -6.4 (-10.1 to -2.0) | -0.3 (-3.5 to 1.5) |
Clinical Worsening events were defined as the number of weeks from first dose date to any of the following: * Hospitalization due to a cardiopulmonary indication (a non-elective hospitalization lasting at least 24 hours in duration caused by clinical conditions directly related to Pulmonary Hypertension and/or Heart Failure) * Administration of intravenous diuretics or subcutaneous (SC) furosemide * Death (all causes) * Decrease in 6 minute walk distance (6MWD) by ≥15% from baseline confirmed by 2 tests at least 4hours, but no more than 1 week apart.
| Months | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo |
|---|---|---|---|
| Base Study: Time to First Clinical Worsening Event (TTCW) at Weeks 24 | NA (NA to NA) | NA (NA to NA) | NA (6.2 to NA) |
mPAP was calculated from systolic and diastolic pulmonary artery pressure measured by right heart catheterization. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
| mmHg | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo |
|---|---|---|---|
| Base Study: Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) at Week 24 | -9.1 (-10.3 to -8.0) | -9.1 (-9.5 to -8.5) | -0.2 (-1.0 to 0.5) |
PCWP is an indirect estimate of left atrial pressure measured in right heart catheterization. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
| mmHg | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo |
|---|---|---|---|
| Base Study: Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 24 | -4.1 (-5.6 to -3.0) | -3.3 (-4.0 to -3.0) | -1.1 (-1.5 to -0.5) |
TAPSE is an echocardiographic measurement of tricuspid valve annulus movement, as an indicator of right heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
| cm | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo |
|---|---|---|---|
| Base Study: Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at Week 24 | -0.2 (-0.2 to 0.0) | -0.1 (-0.2 to -0.1) | -0.2 (-0.2 to -0.1) |
RVFAC is an echocardiographic measurement of percent change between right ventricular area during diastole and systole, as an indicator of right heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
| Percent | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo |
|---|---|---|---|
| Base Study: Change From Baseline in Right Ventricular Fractional Area Change (RVFAC) at Week 24 | 3.1 (2.1 to 4.8) | -1.2 (-2.8 to 2.4) | -0.9 (-2.1 to 1.0) |
LVEF is an echocardiographic measurement of percent change between left ventricular volume during diastole and systole, as an indicator of left heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
| Percent | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo |
|---|---|---|---|
| Base Study: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Week 24 | -1.0 (-2.6 to 0.5) | -2.9 (-4.4 to -1.5) | -0.9 (-2.2 to -0.3) |
IVRT is an echocardiographic measurement of the interval between closure of the aortic valve, to onset of filling by opening of the mitral valve. It was used as an indicator of diastolic dysfunction. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
| msec | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo |
|---|---|---|---|
| Base Study: Change From Baseline in Isovolumic Relaxation Time (IVRT) at Week 24 | 14.8 (-2.0 to 23.0) | 13.1 (7.0 to 25.3) | 6.9 (1.0 to 11.0) |
E/e' is a ratio of mitral inflow velocity E to mitral annular velocity (e') as measured by electrocardiography as an indicator of diastolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
| E/e' ratio | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo |
|---|---|---|---|
| Base Study: Change From Baseline in Ratio of Mitral Inflow Velocity E to Mitral Annular Velocity'(e') (E/e' Ratio) at Week 24 | -0.5 (-1.3 to 0.5) | -1.9 (-2.5 to -0.8) | -0.3 (-0.6 to 0.1) |
E/A is a ratio of the peak velocity flow of the E wave in the early diastole to peak velocity flow of the A wave in late diastole measured by echocardiography as an indicator of diastolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
| E/A ratio | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo |
|---|---|---|---|
| Base Study: Change From Baseline in the Ratio of the Peak Velocity Flow of the E Wave in Early Diastole to Peak Velocity Flow of the A Wave in Late Diastole (E/A Ratio) at Week 24 | -0.1 (-0.2 to 0.0) | -0.2 (-0.3 to -0.1) | 0.1 (-0.1 to 0.4) |
NT-proBNP is a circulating biomarker that reflects myocardial stretch. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
| pg/mL | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo |
|---|---|---|---|
| Base Study: Change From Baseline in N-terminal Pro-hormone Brain Natriuretic Peptide (NT-proBNP) at Week 24 | -100.1 (-119.5 to -86.5) | -171.1 (-214.5 to -153.5) | 157.4 (146.0 to 164.0) |
NYHA FC classified the extent of heart failure (HF). Participant HF symptoms were graded using the NYHA FC system. NYHA FC for HF ranges from Class I (no limitation of physical activity, or ordinary physical activity does not cause undue fatigue, palpitation, dyspnea \[shortness of breath\]), Class II (slight limitation of physical activity, comfortable at rest, or ordinary physical activity results in fatigue, palpitation, dyspnea \[shortness of breath\]), Class III (marked limitation of physical activity, comfortable at rest, or less than ordinary activity causes fatigue, palpitation, or dyspnea) and Class IV (unable to carry on any physical activity without discomfort, symptoms of HF at rest or if any physical activity is undertaken, discomfort increases). Participants were classified as "Improved or Maintained" or "Not Improved nor Not Maintained". Improved or Maintained = reduction in NYHA FC or no change in NYHA FC; Not Improved nor Not Maintained = increase in NYHA FC.
| Participants | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo |
|---|---|---|---|
| Improved NYHA FC or Maintained NYHA FC | 51 | 48 | 45 |
| Not Improved NYHA FC or Not Maintained NYHA FC | 3 | 7 | 10 |
MCF is an echocardiographic measurement that determined the ratio of left ventricular stroke volume to myocardial volume and was an indicator of left ventricular systolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
| Percent | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo |
|---|---|---|---|
| Base Study: Change From Baseline in Myocardial Contraction Fraction (MCF) at Week 24 | 1.6 (-1.0 to 4.0) | -4.1 (-5.0 to -2.5) | -1.1 (-1.6 to -0.9) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE was reported.
| Participants | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo |
|---|---|---|---|
| Base Study: Number of Participants With One or More Adverse Events (AEs) | 49 | 51 | 48 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE was reported.
| Participants | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo |
|---|---|---|---|
| Base Study: Number of Participants Who Discontinued Study Treatment Due to an AE | 0 | 3 | 0 |
Collected over Up to approximately 26 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | 0/54 (0%) | 11/54 (20.4%) | 45/54 (83.3%) |
| Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | 1/56 (1.8%) | 18/55 (32.7%) | 44/55 (80%) |
| Placebo-Controlled Treatment Period: Placebo | 2/55 (3.6%) | 12/55 (21.8%) | 37/55 (67.3%) |
| Extension Period: Sotatercept 0.3 mg/kg | 2/52 (3.8%) | 16/52 (30.8%) | 37/52 (71.2%) |
| Extension Period: Sotatercept 0.7 mg/kg | 3/47 (6.4%) | 16/47 (34%) | 37/47 (78.7%) |
| Extension Period: Placebo → Sotatercept 0.3 mg/kg | 2/22 (9.1%) | 12/22 (54.5%) | 18/22 (81.8%) |
| Extension Period: Placebo → Sotatercept 0.7 mg/kg | 1/23 (4.3%) | 12/23 (52.2%) | 21/23 (91.3%) |
| Event | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo | Extension Period: Sotatercept 0.3 mg/kg | Extension Period: Sotatercept 0.7 mg/kg | Extension Period: Placebo → Sotatercept 0.3 mg/kg | Extension Period: Placebo → Sotatercept 0.7 mg/kg |
|---|---|---|---|---|---|---|---|
| Cardiac failureCardiac disorders | 1/54 | 3/55 | 0/55 | 1/52 | 2/47 | 3/22 | 0/23 |
| HypertransaminasaemiaHepatobiliary disorders | 0/54 | 0/55 | 0/55 | 0/52 | 0/47 | 0/22 | 2/23 |
| Acute kidney injuryRenal and urinary disorders | 2/54 | 1/55 | 0/55 | 1/52 | 2/47 | 0/22 | 2/23 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/54 | 2/55 | 1/55 | 0/52 | 0/47 | 0/22 | 2/23 |
| Angina pectorisCardiac disorders | 0/54 | 0/55 | 0/55 | 0/52 | 0/47 | 1/22 | 1/23 |
| Atrial fibrillationCardiac disorders | 0/54 | 1/55 | 1/55 | 1/52 | 0/47 | 1/22 | 1/23 |
| Atrial flutterCardiac disorders | 1/54 | 0/55 | 0/55 | 0/52 | 1/47 | 1/22 | 0/23 |
| Cardiac failure acuteCardiac disorders | 1/54 | 0/55 | 0/55 | 0/52 | 0/47 | 1/22 | 0/23 |
| Pericardial effusionCardiac disorders | 0/54 | 0/55 | 0/55 | 0/52 | 0/47 | 1/22 | 0/23 |
| Ventricular dysfunctionCardiac disorders | 0/54 | 0/55 | 0/55 | 0/52 | 0/47 | 1/22 | 0/23 |
| Event | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo | Extension Period: Sotatercept 0.3 mg/kg | Extension Period: Sotatercept 0.7 mg/kg | Extension Period: Placebo → Sotatercept 0.3 mg/kg | Extension Period: Placebo → Sotatercept 0.7 mg/kg |
|---|---|---|---|---|---|---|---|
| FallInjury, poisoning and procedural complications | 1/54 | 5/55 | 4/55 | 6/52 | 4/47 | 5/22 | 5/23 |
| Upper respiratory tract infectionInfections and infestations | 0/54 | 3/55 | 4/55 | 5/52 | 2/47 | 1/22 | 5/23 |
| DizzinessNervous system disorders | 6/54 | 7/55 | 4/55 | 5/52 | 5/47 | 3/22 | 5/23 |
| Haemoglobin increasedInvestigations | 10/54 | 5/55 | 1/55 | 2/52 | 4/47 | 0/22 | 1/23 |
| HypokalaemiaMetabolism and nutrition disorders | 0/54 | 3/55 | 2/55 | 1/52 | 1/47 | 4/22 | 1/23 |
| HeadacheNervous system disorders | 3/54 | 7/55 | 5/55 | 4/52 | 2/47 | 4/22 | 4/23 |
| HypotensionVascular disorders | 0/54 | 3/55 | 1/55 | 4/52 | 3/47 | 4/22 | 2/23 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/54 | 1/55 | 5/55 | 8/52 | 3/47 | 2/22 | 4/23 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/54 | 0/55 | 5/55 | 9/52 | 3/47 | 3/22 | 2/23 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 7/54 | 6/55 | 4/55 | 6/52 | 8/47 | 3/22 | 1/23 |
| Age, Continuous(Years) | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo | Total |
|---|---|---|---|---|
| Mean | 74.1 ± 7.4 | 72.0 ± 8.1 | 72.7 ± 9.2 | 72.9 ± 8.3 |
| Sex: Female, Male(Participants) | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo | Total |
|---|---|---|---|---|
| Female | 35 | 43 | 36 | 114 |
| Male | 19 | 13 | 19 | 51 |
| Ethnicity (NIH/OMB)(Participants) | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 0 | 3 |
| Not Hispanic or Latino | 46 | 52 | 53 | 151 |
| Unknown or Not Reported | 5 | 4 | 2 | 11 |
| Race (NIH/OMB)(Participants) | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 1 | 2 | 7 |
| White | 46 | 52 | 52 | 150 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 3 | 1 | 8 |
| NYHA Functional Class(Participants) | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo | Total |
|---|---|---|---|---|
| Class II | 17 | 19 | 20 | 56 |
| Class III | 37 | 36 | 35 | 108 |
| Missing | 0 | 1 | 0 | 1 |
| PVR(dynes*sec/cm5) | Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg | Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg | Placebo-Controlled Treatment Period: Placebo | Total |
|---|---|---|---|---|
| Mean | 464.1 ± 207.9 | 446.1 ± 196.7 | 423.4 ± 169.9 | 444.4 ± 191.6 |
Showing the first 100 of 119 sites across 12 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Dec 2021 to primary completion in Sep 2025, 44 months.
Results were first posted in Sep 2026, 1 year after primary completion.
Of 50 phase 2 interventional studies under Hypertension, Pulmonary, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 71. This study's 44 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotatercept
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA →